B hepatitis and liver transplantation

G. Ferla, M. Colledan, M. Doglia, L. R. Fassati, M. Gislon, B. Gridelli, G. Rossi, D. Galmarini

Research output: Contribution to journalArticlepeer-review


Herein is reported our experience in treating with a liver transplant 14 HBsAg+ patients affected by end-stage liver disease; among these, nine patients were or had been also superinfected with HDV. An attempt has been made to evaluate the course of possible HBV reinfection and its correlation to HDV coinfection in patients who survived more than 3 months. Our results suggest that OLTX must also be performed in HBsAg carriers, even if serological signs of HBV virulence or HDV coinfection are present, to have a good outcome and quality of life. OLTX must also be performed if patients develop posttransplant B/D viral hepatitis recurrence. Future efforts must be directed toward best identifying recurrences, improving active and passive prophylaxis-mainly the long-term one-monitoring HBsAG titer, and evaluating the oppportunity of pretransplant treatment with interferon, to which HDV especially seems to be sensitive.

Original languageEnglish
Pages (from-to)566-569
Number of pages4
JournalTransplantation Proceedings
Issue number1 SUPPL. 1
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'B hepatitis and liver transplantation'. Together they form a unique fingerprint.

Cite this